💨 Abstract

Protagonist Therapeutics Inc. (PTGX) reported a Q2 loss of $34.8 million, or 55 cents per share, falling short of analyst expectations of a 53 cents per share loss. Revenue was $5.5 million, significantly below the forecasted $10.4 million. The Newark, California-based biopharmaceutical company's performance did not meet Wall Street forecasts for both earnings and revenue.

Courtesy: WTOP Staff